NCT06624878

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Intraoperative Esketamine for Prevention of Depressive Symptoms After Cytoreductive Surgery in Ovarian Cancer: a Controlled, Randomized Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 568 (actual)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer. The main questions it aims to answer are: * Whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer? * Whether a single low dose of esketamine administered would relief the postoperative sleep disturbance, postoperative recovery? Researchers will compare the esketamine to a placebo (normal saline) to see if the esketamine works to reduce the postoperative depressive symptoms. Participants will: * Receive either 0.2 mg/kg esketamine or placebo infused intravenously after induction of general anesthesia. * The preoperative Patient Health Questionnaire 9 (PHQ-9) scale was used to verify the symptoms suggestive of depression.

Conditions

• Ovarian Cancer
• Cytoreductive Surgery
• Depressive Symptom

Interventions

Type	Name	Description
DRUG	esketamine	0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
DRUG	placebo	a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.

Timeline

• Start date: 2024-10-08
• Primary completion: 2026-01-14
• Completion: 2026-02-14
• First posted: 2024-10-03
• Last updated: 2026-02-27

Locations

1 site across 1 country: China